Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: masunaga a. Urol Oncol. 2017 Feb;35(2):39.e19-39.e28. doi: 10.1016/j.urolonc.2016.10.001. Epub 2016 Nov 4. Urol Oncol. 2017. PMID: 27825515
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: masunaga a. Urol Oncol. 2016 Jul;34(7):293.e17-25. doi: 10.1016/j.urolonc.2016.02.023. Epub 2016 Apr 1. Urol Oncol. 2016. PMID: 27040380
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M. Shirotake S, et al. Among authors: masunaga a. Clin Genitourin Cancer. 2016 Dec;14(6):e575-e583. doi: 10.1016/j.clgc.2016.03.014. Epub 2016 Mar 24. Clin Genitourin Cancer. 2016. PMID: 27102405
Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer.
Ito K, Soga S, Seguchi K, Shinchi Y, Masunaga A, Tasaki S, Kuroda K, Sato A, Asakuma J, Horiguchi A, Shinmoto H, Kaji T, Asano T. Ito K, et al. Among authors: masunaga a. Oncol Lett. 2017 Jul;14(1):918-924. doi: 10.3892/ol.2017.6262. Epub 2017 May 26. Oncol Lett. 2017. PMID: 28693252 Free PMC article.
External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.
Tanaka N, Mizuno R, Ito K, Shirotake S, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: masunaga a. Eur Urol Focus. 2016 Aug;2(3):303-309. doi: 10.1016/j.euf.2015.11.001. Epub 2015 Dec 2. Eur Urol Focus. 2016. PMID: 28723377
119 results